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Objectives: To evaluate the effect of low molecular weight heparin (LMWH), dextran 70 and their combination on platelet 
adhesion and fibrinogen uptake in ePTFE grafts in an experimental sheep model. 
Design: Prospective open study. 
Setting: Animal Laboratory of a University Hospital. 
Materials: Early thrombogenicity of ePTFE grafts was studied after interposition in the two common carotid arteries of 
40 adult sheep. The animals received one of four different treatment regimens in a double blind randomised way: enoxaparin 
and polygeline, saline and dextran 70, enoxaparin and dextran 70 or saline and polygeline (control). The substances were 
administered i.v. with a total dose of 73 antifactor-Xa U/kg for enoxaparin and 1.O g/kg for dextran 70. Polygeline and 
saline were used as placebo substances in equivalent volumes. On one side (random allocation) the carotid blood flow was 
restricted to 25 ml/min, on the other side it was left unrestricted. 
Chief outcome measures: The following variables were studied: 1) fibrinogen uptake; 2) platelet uptake; 3) early graft 
patency; 4) blood flow in patent grafts; 5) visible presence of graft thrombus; 6) thrombus weight. 
Main results: The results verified the importance of adequate blood flow as only 30% of grafts with restricted blood flow 
in the control group were patent compared with 80% of those with unrestricted blood flow (p = 0.038). Dextran 70, 
enoxaparin and the combination of the two increased early graft patency (p < 0.05) and reduced thrombus weights 
(p < 0.05) in grafts with restricted blood flow. The relative number of grafts with thrombus free surface was increased in 
the unrestricted blood flow situation. 
Conclusions: Dextran 70 and enoxaparin appeared to be equally effective in decreasing fibrinogen and platelet uptake in 
the grafts. Their combination was not significantly more effective although there was a favourable trend. 
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Fibrinogen uptake. 
Introduction 
There are several reasons why the early- and long- 
term graft patency after arterial bypass reconstruction 
is limited. Technical errors, high peripheral resistance, 
low blood flow and the thrombogenicity of the graft 
material may lead to graft occlusion. 1 Blood abnor- 
malities such as increased platelet adhesiveness 2 and 
decreased fibrinolytic activity in the postoperative 
period 3 may also affect the outcome. Furthermore, 
patients with atherosclerotic disease frequently have 
an elevated hematocrit and increased blood viscosity. 4 
Probably the best arterial substitute available is the 
autologous vein. s' 6 However, the vein is not always 
available and the use of prosthetic material, with 
higher thrombogenicity may lead to decreased 
patency. 
Clinical data show that an increased postoper- 
ative platelet uptake in grafts is related to reduced 
1-year patency 7 making studies of pharmacological 
adjuvant herapy to increase graft survival of interest. 
Several clinical and experimental studies have focused 
on this problem. Various antiplatelet agents such as 
8 acetyl salicylic acid alone or combined with dipyr- 
idamol 9,10 agents blocking the synthesis of thrombox- 
ane, 11 the thromboxane receptor 12 or both 13 seem to 
diminish graft thrombogenicity. Dextran 40 also 
improves early graft patency in humans. ~4 Experi- 
mental studies have also shown favourable ffects of 
dextran 40, increasing early graft patency 15 and 
1078-5884/95/030284 + 09 $08'00/0 © 1995 W. B. Saunders Company Ltd. 
Effect of Dextran and Enoxaparin on Early ePTFE Graft Thrombogenicity in Sheep 285 
reducing leukocyte ~6 and platelet adhesion. 17 Sim- 
ilarl3~ unfractionated heparin (UH) has been used in 
vascular econstructive surgery since the 40s ~s intra- 
operatively and postO~geratively and even bound to 
the prosthetic surface. 9 
After the development of low molecular weight 
heparin (LMWH) the use of UH has diminished in 
venous thromboprophylaxis) °'2~ In arterial recon- 
structive surgery LMWH is inadequately documented 
with only few studies published. 22"-~9 Experimental 
data indicate that LMWH may augmentate he antith- 
rombotic effects of dextran when used in venous 
thromboprophylaxis 3° without affecting 
haemostasis.3~, a2 
The aim of this study was to evaluate the effect of 
LMWH, dextran 70 and their combination on platelet 
adhesion and fibrinogen uptake in ePTFE grafts in an 
experimental sheep model. 
Material and Methods 
The study was approved by the Ethics Committee for 
Laboratory Animal Research, Lund Universit3~ Swe- 
den, and conducted according to the rules of Euro- 
pean Convention for Laboratory Animal Care. 
Animals 
Forty apparently healthy adult Swedish farm sheep of 
both sexes were studied. The median body weight was 
27 kg (range 22-34 kg). The sheep were fed a standard 
diet and given water ad libitum. A leg vein cannula 
(Venflon®, BOC Ohmeda, Sweden) was used for 
injection of anaesthetics and test substances. The 
animals were anaesthetised with sodium penthobarbi- 
tal (Pentothal® Sodium 25mg/ml) and intubated. 
Respiration was maintained with a respirator (Cervo 
900, Siemens Elema, Sweden) with a mixture of 
oxygen (50 to 65%) and nitrous oxide (50 to 35%), at a 
volume of 5.0 to 7.51/rain and monitored with 
frequent blood gas analyses. The blood pressure was 
monitored continuously. Anaesthesia was maintained 
with a continuous infusion of sodium pentothal 
2.5% (0.15 to 0.3ml/min). Adequate hydration was 
maintained with a continuous infusion of saline 
(80 ml/h). 
Radionuclide labelling 
Sixty ml of blood from a jugular vein was used to 
prepare a platelet rich plasma suspension. The platelet 
fraction was examined by microscopy for contamina- 
tion and for the amount of cells available for radio- 
nuclide labelling. The platelets were labelled with 
12.5MBq ~llindium oxinate with a half-life of 67.4 
hours (DRN 4908 Indium oxinate, Mallinckrodt Medi- 
cal The Netherlands). ~3 The platelet fraction was then 
checked in a gamma counter for labelling efficiency 
(Fig. 1). The fibrinogen used in the investigation was a 
sheep fibrinogen delivered in a pre-labelled suspen- 
sion according to McFarlane. 34 The amount used in 
each sheep was 1.0 ml labelled with 2MBq ~iodine 
(Amersham International U.K.). 
Experimental model 
The sheep were positioned in a supine position and 
through a 30 cm ventral midline neck incision both 
carotids were exposed. Small tributaries were ligated 
and divided. The carotids were wrapped in a thin 
plastic film to assure moisture and placed in separate 
lead collimators, one on each side. Four sodium 
iodine, gamma radiation detectors (Model 
0.91 × M.510/.75 BLP-X, Bicron, U.S.A.) were placed 
in the collimators, two detectors on each side. The 
detectors were connected to a multi-channel analyser 
set up (EG & G Ortec, Nuclear Systems, U.S.A.) and a 
personal computer (Victor 486) for detection of signals 
that were stored simultaneously in the computer. The 
sheep were covered with a lead apron to minimise 
scattered radiation interference. After injection of the 
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Fig. 1. Platelet harvest (platelets × 10S)-left, and platelet labelling 
efficiency (%)-right, in the groups studied (mean_+ S.E.M.). No 
statistical difference was found between the four groups. 
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mindium labelled platelets and the 125iodine labelled 
fibrinogen, baseline isotope activity was measured 
during five 2 rain intervals. This activity was used as 
baseline for the uptake measurements in the ePTFE 
grafts in the individual sheep. After the baseline 
isotope uptake measurements, the carotids were 
clamped and partially resected. The vessels were 
flushed with isotonic saline to prevent hrombosis but 
heparin was not used. An 11.5 cm thin-walled ePTFE 
graft, 6mm in diameter (Gore-Tex TM, Gore & Asso- 
ciates, Inc., U.S.A.) was interpositioned in each carotid 
vessel with an oblique end to end anastomosis with a 
running suture of CV 7.0, Gore-Tex TM (Gore & Asso- 
ciates, Inc., U.S.A.). The flow was re-established on 
both sides simultaneously and free vessel/graft low 
was allowed for 5 min to ensure haemostasis n the 
anastomosis. The vessels were again wrapped in a 
thin plastic film and placed in the lead collimators, one 
on each side. To increase the thrombogenicity of the 
graft and to mimic a poor run-off situation the flow 
was restricted to 25ml/min (+20%) in one carotid 
(randomly selected) with a specially made flow- 
restriction clamp, on the native artery distal to the 
distal anastomosis. The contralateral carotid had an 
unrestricted blood flow. The blood flow was mon- 
itored simultaneously in both carotids with a transit 
time ultrasound flow meter (TC 101, Transonic Inc., 
U.S.A.) and registered in a Macintosh TM computer 
with CHART/4 - Mac Lab TM software (Analog Digital 
Instrument, U.S.A.) for later analysis. The ultrasound 
probes were placed on the native arteries proximal to 
the proximal anastomosis. The four sodium iodine, 
gamma radiation detectors were placed in the collima- 
tors and the radionuclide uptake measured in the 
ePTFE graft 1.5 cm from the anastomosis. The uptake 
was measured uring 3h 20rain (200 min) in repeated 
2 min intervals. The occurrence of graft occlusion was 
registered with the transit ime ultrasound flowmeter. 
After the observation time the grafts were removed 
and opened lengthways and inspected for the pres- 
ence of visible thrombus. Any thrombus was removed 
from the graft in a standard manner by scraping the 
graft. The excess fluid was removed with absorption 
paper and the thrombus weighed. 
Substances 
The following substances were used: Enoxaparin 
(Klexane®, Rh6ne-Poulenc Rorer, France). Mean 
molecular weight 4500 Da. Declared specific activity 
100 antifactor-Xa U/mg. The total injected dose was 
73 antifactor-Xa U/kg body weight i.v., with a starting 
dose of 55 antifactor-Xa U/kg repeated with one third 
of the starting dose (18 antifactor-Xa U/kg) after 2 h. 
Dextran 70 (Macrodex® with sodium chloride, Phar- 
macia, Sweden) with a mean molecular weight of 
70 000 Da. The total dose was 1.0 g/kg body weight 
(16.5 ml/kg) by i.v. route during 30 rain. Prior to the 
dextran infusion 20ml of dextran 1 (Promiten®, 
Pharmacia, Sweden) was given intravenously tocheck 
for possible anaphylactic reactions. 35 Polygeline (Hae- 
maccel®, Behring, Germany) was used as a placebo 
substance for dextran for volume expansion. It has a 
molecular weight of 5000-15 000 Da with no antith- 
rombotic or fibrinolytic effects and a negligible effect 
on platelet function. 36'37 The infused polygeline dose 
was 16.5 ml/kg body weight. Saline (0.9% NaC1) was 
used as placebo substance for enoxaparin and dextran 
1. 
Experimental design 
In a blind randomised fashion the animals received 
one of four treatment regimes. 1) Saline with polyge- 
line (control group), 2) Enoxaparin with polygeline, 3) 
Enoxaparin with dextran, 4) Saline with dextran. Ten 
animals were included in each treatment group. The 
test solutions were prepared separately for individual 
animals in coded vials and the investigator was 
unaware of the given treatment. The polygeline and 
dextran was infused during the insertion of the grafts. 
The enoxaparin or respective placebo substance 
(saline) were injected during the haemostatic pause 
when the flow was re-established after the insertion of 
the grafts. The doses of the test substances were based 
on recommendations by the manufacturer for venous 
thromboprophylaxis in clinical practice for high risk 
situations. Due to the short half-life of LMWH 38 after 
i.v. injection in sheep a further dose, one third of the 
original dose, was given after 2 h. The following 
variables were studied: 1) fibrinogen uptake, 2) plate- 
let uptake, 3) early graft patency, 4) blood flow in 
patent grafts, 5) visible presence of graft thrombus 6) 
thrombus weight. 
Statistical analysis 
The values are expressed as mean+S.E.M, unless 
otherwise stated. The radionuclide uptake was ana- 
lysed and related to the baseline radionuclide uptake. 
The resulting curves show the relative change in 
uptake when compared with the baseline measure- 
ments. The results were evaluated with Mann-Whit- 
ney U test. Fischer's exact test was used to evaluate 
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Fig. 2. Early graft patency (%). *p<0.05 when compared with 
respective control group. Patency was ignificantly lower in the 
control group with restricted blood flow when compared with the 
group with unrestricted blood flow (p = 0.038). 
early graft patency and frequency of visible thrombus. 
A confidence level of <5% was considered 
significant. 
Results 
No adverse effects or bleeding complications were 
observed uring the study. All animals survived the 
observation period and were sacrificed at the end of 
the experiment. 
Early graft patency 
The three treatment regimens ignificantly increased 
the early graft patency in the restricted flow system 
(Fig. 2). Seven grafts occluded in the control group 
with restricted blood flow (median 61 min, range 
30-100). One graft with restricted blood flow occluded 
in the enoxaparin treated group and one in the dextran 
treated group at 135 and 190 min respectively. Two 
grafts with unrestricted blood flow occluded in the 
control group after 60 and 150 min. One graft 
occluded in the enoxaparin treated group and one in 
the dextran treated group after 100 and 105 min 
respectively with unrestricted blood flow. No occlu- 
sion occurred in the enoxaparin/dextran treated 
group with restricted or unrestricted blood flow. No 
technical errors that may have resulted in graft 
occlusion were observed in the occluded grafts. The 
graft with unrestricted blood flow that occluded after 
150 min had lower flow than the other grafts in the 
control group, during the whole observation period. 
The reason for this is unknown but the animal also 
had a lower arterial pressure than the other animals in 
the group. A wide variation in blood flow was 
observed in the vessels with unrestricted blood flow 
(43-395ml/min). Generally the flow in the patent 
grafts tended to increase successively during the 
observation period but no statistical differences were 
observed between or within the groups. 
Thrombus 
All grafts in the control groups had some thrombus. 
No thrombus-free surface was seen in the control 
group with restricted flow. Generally the mural 
thrombi were more pronounced in the anastomotic 
regions with their thickest part distally. The thrombi n 
the grafts with unrestricted blood flow were generally 
"whitish" and thin but more compact han the more 
"reddish" thrombi n the grafts with restricted blood 
flow, irrespective of given treatment. The groups 
treated respectively with enoxaparin, dextran or their 
combination had thrombus-free surface in 50, 50 and 
60% of grafts with unrestricted blood flow (p < 0.05 
when compared with the control group). Two grafts 
with restricted blood flow in the group treated with 
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Fig. 3. Mean thrombus weights (g + S.E.M.). *p < 0.05 compared with 
the control group. The mean thrombus weights were loWer in the 
control group with unrestricted blood flow when compared with 
restricted blood flow (p = 0,04). 
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Fig. 4. Relative fibrinogen uptake in grafts with restricted blood flow based on baseline uptake. Left: proximal part of the grafts. Right: distal 
part of the grafts. Each column represents average uptake during 22 min interval (mean _+ S.E.M.). *p < 0.05 compared with controls. 
enoxaparin and dextran and one treated with enox- 
aparin had no visible mural thrombus at all. 
The mean thrombus weights were significantly 
lower in the treatment groups with restricted blood 
flow than in the control group (Fig. 3); enoxaparin 
p=0.045, dextran p=0.04 and enoxaparin/dextran 
p=0.002. No similar reduction was een in the 
treatment groups with unrestricted blood flow. 
Radionuclide activity 
In grafts with restricted blood flow, all three treatment 
groups were similar in fibrinogen and platelet uptake 
without significant difference between them (Figs 4 
and 5). Although there was a numerically higher 
uptake in the control group this was only significant in 
the first 44 min for both fibrinogen and platelets 
except for fibrinogen in the proximal part of the grafts. 
The uptake has only been calculated in patent grafts. 
The control group therefore "faded out" as the grafts 
occluded during the observation period. 
In grafts with unrestricted blood flow, the treat- 
ment regimens significantly reduced the fibrinogen 
uptake for the first 88 min in the proximal part of the 
grafts and in the entire distal part, except in some 
sporadic measurements, when compared with the 
control group (Figs 6 and 7). The platelet uptake was 
similarly reduced in the treatment groups for up to 
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Fig. 5. Relative platelet uptake in grafts with restricted blood flow based on baseline uptake. Left: proximal part of the grafts. Right: distal 
part of the grafts. Each column represents average uptake during 22 •in interval (mean + S.E.M.). *p < 0.05 compared with controls. 
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Fig. 6. Relative fibrinogen uptake in the proximal part of grafts with unrestricted blood flow based on baseline uptake. Each column 
represents average uptake during 22 minutes interval (mean _+ S.E.M.). *p < 0.05 compared with controls. 
132 min in the distal part of the grafts but not in the 
proximal part (Figs 8 and 9). 
Discussion 
Graft performance in clinical practice depends on 
several factors which can be classified according to 
Virchow's triad: the surface of the prosthesis; the 
blood flow; and the characteristics of the circulating 
blood. Low blood flow, secondary to poor in- or 
outflow, appears to be one of the most important 
factors associated with reduced graft patency. 39 How- 
ever, the flow situation is difficult to improve except 
when based on pure technical error or by increasing 
the graft flow by distal AV-fistula. Autogenous venous 
graft material is still superior to prosthetic material in 
long term patency) 4'4o In cases where an autologous 
vein cannot be harvested, prosthetic material is the 
only material available for arterial reconstruction. 
Several experimental nd clinical studies have sug- 
gested that ePTFE grafts are superior to Dacron in 
terms of patency and platelet adhesion. 7' 25 However, 
this appears to be true only in the immediate intra- 
and postoperative period as after 6 months there was 
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Fig. 7. Relative fibrinogen uptake in the distal part of grafts with unrestricted blood flow based on baseline uptake. Each column represents 
average uptake during 22 rain interval (mean _+ S.E.M.), *p < 0.05 compared with controls, 
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Fig. 8. Relative platelet uptake in the proximal part of gr fts with unrestricted blood flow based on baseline uptake. Each column represents 
average uptake during 22 rain interval (mean _+ S.E.M.). 
no difference 42 and with time, all grafts, including 
autologous veins, biological as well as prosthetic 
substitutes, develop thrombogenic surface alterations. 
Low flow, high intra- and postoperative thromboge- 
nicity and possible thrombogenic blood factors make 
adjuvant pharmacological treatment to decrease the 
risk of graft thrombosis attractive. 
In the present study we investigated the effect of 
dextran 70 and enoxaparin on ePTFE platelet adhe- 
sion, fibrinogen uptake and graft patency. The two 
substances have different mechanisms of action. The 
antithrombotic effect of enoxaparin is partially medi- 
ated through inhibition of factor Xa and to a lesser 
extent of factor IIa. 43 It also affects platelets, endothe- 
lium and fibrinolysis. 44 Dextran 70 is volume expand- 
ing, to an extent comparable to albumin and gelatin, 
and flow promoting 45' 46 it coats the blood corpuscles 
and endothelium with a dextran film, 47 changes the 
structure of fibrin 48 and thrombi 49 and enhances 
lysability of the thrombus. 5° Furthermore, dextran 
decreases platelet adhesiveness to foreign surfaces 
with peak effect 2 to 6 h after infusionY Von 
Willebrand factor (factor VIII related antigen) is 
decreased in the presence of dextran but other 
coagulation factors only to an extent which can be 
explained by the haemodilution. 5°'52'53 Polygeline, 
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Fig. 9. Relative platelet uptake in the distal part of grafts with unrestricted blood flow based on base ine uptake. Each column represents 
average uptake during 22 min interval (mean _+ S.E.M.). *p < 0.05 compared with controls. 
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that has no thromboprophylactic properties and does 
not affect coagulation or haemostasis 36'37,41, 54 was 
used in the present study for volume expansion. The 
initial volume expansion effect is similar to that of 
dextran 70 but of shorter duration. 36' 41, 55 However, 3 
to 4 h after infusion similar volume expansion is 
achieved in animals. 56 The purpose of using polyge- 
line in the control group was to correct for the volume 
expansion effects of dextran 70. After 20, 90 and 180 
rain there was no significant difference in blood flow 
between the groups. 
The experimental model used in the present 
study simulates situations with different expected 
patency rates: one highly thrombogenic low flow 
system and another less thrombogenic high flow 
system. The results verify the importance of adequate 
blood flow. The grafts with restricted blood flow in the 
control group were patent in 30% compared with 80% 
of grafts with unrestricted flow (p = 0.038). The tested 
substances did not influence the patency or thrombus 
weights when there was unrestricted blood flow 
(although numerical differences were observed). 
However, the grafts were significantly more often 
thrombus-free than in the control group. The sub- 
stances appeared to affect mainly the distal part of the 
graft where the deposition of platelets and fibrinogen 
was highest. 
In restricted blood flow, the treatments influenced 
thrombus weight as much as patency but not throm- 
bus-free surface. The graft loss due to early occlusion 
makes statistical analysis with a limited number of 
patent grafts in the control group less valid after 88 
min regarding platelet- and fibrinogen uptake but the 
values were numerically higher when compared with 
the control groups. In conclusion in the present study 
dextran 70 and enoxaparin appear equally effective in 
decreasing early thrombogenicity. Their combination 
is not significantly more effective although there was a 
favourable trend. 
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